Make your drugs soluble with Dispersome®

The Dispersome® technology allows formulation of poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.

Dispersome® - An enabling technology for low solubility drugs


Our Dispersome® platform is based around a class of novel excipients to formulate poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.


By increasing solubility and dissolution rate the Dispersome® platform aims at improving bioavailability, therapeutic outcomes and convenience for patients.


Dispersome® formulations are compatible with standard solid oral dosage form manufacturing processes and facilities.

Advancing with Dispersome® Technology

Some of our industry partners. We are delighted to have established partnerships with prominent pharmaceutical companies that have adopted our Dispersome® Technology. These valued collaborations underscore our commitment to advancing drug solubility, positively impacting patient well-being, and shaping the future of drug delivery.

Learn more  →

Zerion Pharma News

lab equipment
Press Releases
February 15, 2024

dsm-firmenich and Zerion Pharma form a partnership to develop improved cannabinoids

First Cannabidiol drug formulation from partnership to enter clinical studies in 2024.

lab equipment
Zerion in the news
October 17, 2023

Zerion Pharma featured in Pharmaceutical Technology

Zerion Pharma is featured as an innovative start-up by Pharmaceutical Technology in their ‘Trends in Formulation 2023’ eBook, October 2023.

lab equipment
Press Releases
September 25, 2023

Zerion Pharma A/S elects Carl-Åke Carlsson as Chairman of the Board

September 25, 2023 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces that the Company has elected Mr. Carl-Åke Carlsson as its new Chairman of the Board of Directors.

More news

Zerion Pharma in Press

Zerion in the Literature

Scientific Publications

Xuezhi Zhuo, Vito Foderà, Per Larsson, Zarah Schaal, Christel A.S. Bergström, Korbinian Löbmann, Aleksei Kabedev. "Analysis of stabilization mechanisms in β-lactoglobulin-based amorphous solid dispersions by experimental and computational approaches”. European Journal of Pharmaceutical Sciences 2024, 192, 106639.

Xuezhi Zhuo, Zeyneb Sener, Aleksei Kabedev, Min Zhao, Anis Arnous, Donglei Leng, Vito Foderà, and Korbinian Löbmann. "Mechanisms of Drug Solubility Enhancement Induced by β-Lactoglobulin-Based Amorphous Solid Dispersions." Molecular Pharmaceutics 2023, 20 (10), 5206-5213.

Leng D, Bulduk B, Widmer T, Wiborg O, Sanchez-Felix M, Löbmann K. "Protein based amorphous solid dispersions: a case study investigating different whey proteins at high drug loading." Pharmaceutical Research, 2023.

Leng D, Bulduk B, Anlahr J, Müllers W, Löbmann K. "Enhanced dissolution rate of nimodipine through β-lactoglobulin based formulations." International Journal of Pharmaceutics, 2023, 635, 122693.


Xuezhi Zhuo, et al. "A Comparative Study between A Protein Based Amorphous Formulation and Other Dissolution Rate Enhancing Approaches: A Case Study with Rifaximin." Pharmaceutics 15.1 (2022): 126.

Kabedev A, Zhuo X, Leng D, Foderà V, Larsson P, Bergström CAS, Löbmann K. "Stabilizing Mechanisms of β-Lactoglobulin in Amorphous Solid Dispersions of Indomethacin." Molecular Pharmaceutics 2022, 19 (11), 3922-3933.


Mishra J, Bohr A, Rades T, Grohganz H, Löbmann K. "Whey proteins as stabilizers in amorphous solid dispersions". European Journal of Pharmaceutical Sciences, 2019, 128, 144-151